Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Phthalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalic Acid SCHEMBL3914680 | 0.97 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL30001010 | 0.97 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL109123 | 0.97 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL8690025 | 0.94 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL21494484 | 0.94 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL11216044 | 0.94 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL195821 | 0.94 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL486782 | 0.94 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL120006 | 0.94 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDCA2CA4 | |
| Phthalic Acid SCHEMBL7897478 | 0.94 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDCA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146092-A1 | DUAL SPECIFICITY ANTIBODIES TO HUMAN PD-L1 AND PD-L2 AND METHODS OF USE THEREFOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-28 | — | — | US | disclosed |
| US-12637518-B2 | Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026102432-A1 | HUMAN ANTIBODIES TO MARBURG VIRUS AND METHODS OF USE THEREFOR | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260109765-A1 | MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720675-A2 | HUMAN MONOCLONAL ANTIBODIES FOR HUMAN PARAINFLUENZA VIRUS TYPE 3 | Vanderbilt University (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12596122-B2 | LILRB2 antibodies and uses thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4705352-A1 | BDCA2-TARGETING ANTIBODIES AND USES THEREOF | Inmagene Pte. Ltd. (SG) | 2026-03-11 | — | — | EP | disclosed |
| EP-4698566-A2 | AGNONISTIC ANTIBODIES TARGETING JAML | La Jolla Institute for Immunology (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12559545-B2 | Human hendra virus and nipah virus antibodies and methods of use therefor | VANDERBILT UNIVERSITY (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4694914-A1 | INHIBITION OF: STROMA/CANCER CELL CROSS-TALK &/OR STROMA GENERATED RESISTANCE TO TREATMENT | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | disclosed |
| EP-0412050-B1 | Novel cytokines | CIBA GEIGY AG (CH) | 1995-12-20 | — | — | EP | disclosed |
| US-5468468-A | Antitumor agents; medical diagnosis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1995-11-21 | — | — | US | disclosed |
| US-5411882-A | Cytokine which mediates inflammation | CIBA-GEIGY CORPORATION (US) | 1995-05-02 | — | — | US | disclosed |
| EP-0640131-A1 | GENETICALLY ENGINEERED ANTIBODIES | Novartis AG (CH) | 1995-03-01 | — | — | EP | disclosed |
| WO-1995000659-A1 | MONOCLONAL ANTIBODIES AGAINST THE ALPHA PDGF RECEPTOR AND USES THEREOF | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-01-05 | — | — | WO | disclosed |
| EP-0589840-A1 | Reshaped monoclonal antibodies against an immunoglobulin isotype | CIBA-GEIGY AG (CH) | 1994-03-30 | — | — | EP | disclosed |
| WO-1993019180-A1 | GENETICALLY ENGINEERED ANTIBODIES | CIBA-GEIGY AG (CH) | 1993-09-30 | — | — | WO | disclosed |
| EP-0519866-A1 | Novel anti-HIV antibodies | CIBA-GEIGY AG (CH) | 1992-12-23 | — | — | EP | disclosed |
| EP-0498767-A2 | Chimeric antiidiotypic monoclonal antibodies | CIBA-GEIGY AG (CH) | 1992-08-12 | — | — | EP | disclosed |
| EP-0412050-A1 | Novel cytokines | CIBA-GEIGY AG (CH) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12596122-B2 | LILRB2 antibodies and uses thereof | FCGR3B, IL2RA, LIFR | ALDH1A1 4032/4885KDM4E 3095/4885HPGD 4656/4885 |
| US-20260109765-A1 | MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF | F13A1, CA13, MICA | ALDH1A1 3814/4885KDM4E 2587/4885HPGD 4809/4885 |
| US-12637518-B2 | Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor | PDCD1LG2, CD274, PDCD1 | ALDH1A1 2813/4885KDM4E 774/4885HPGD 4822/4885 |
| US-20260146092-A1 | DUAL SPECIFICITY ANTIBODIES TO HUMAN PD-L1 AND PD-L2 AND METHODS OF USE THEREFOR | PDCD1LG2, PDCD1, CD274 | ALDH1A1 2835/4885KDM4E 1991/4885HPGD 4709/4885 |
| US-12559545-B2 | Human hendra virus and nipah virus antibodies and methods of use therefor | VSIG8, IGSF11, NIPSNAP1 | ALDH1A1 3333/4885KDM4E 4027/4885HPGD 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.